Key Points
Paul te Boekhorst received 25,329 non-qualified stock options at $5.90 per share
Form 3 filing establishes baseline holdings for SEC tracking purposes
Option grant valued at approximately $149,441 signals management confidence
Investors should monitor future Form 4 filings for CEO stock activity
Insider trading filings reveal what company leaders really think about their stock. When executives file paperwork with the SEC, it signals confidence or caution. Today we examine a significant insider transaction at ICCC (ImmuCell Corporation). Paul Francis Olivier te Boekhorst, the company’s President and CEO, filed an initial ownership disclosure in November 2025. The filing covers a non-qualified stock option grant worth approximately $149,441. This insider transaction offers insight into executive compensation and leadership confidence in the biotech firm’s future direction.
Understanding the ICCC Insider Transaction
ImmuCell Corporation disclosed a significant insider transaction through an SEC Form 3 filing. Paul Francis Olivier te Boekhorst, serving as Director and President/CEO, reported a non-qualified stock option grant. The filing occurred on November 7, 2025, covering options dated September 16, 2028.
Stock Option Grant Details
The insider transaction involved 25,329 shares through a non-qualified stock option (right to buy). The exercise price was set at $5.90 per share, valuing the total grant at approximately $149,441. Non-qualified stock options differ from incentive stock options in tax treatment. They provide executives flexibility in compensation structure. This grant represents a standard executive incentive arrangement in the biotech sector.
Form 3 Filing Significance
A Form 3 filing is an initial ownership statement required when insiders first acquire reportable securities. The SEC filing establishes the baseline for tracking future transactions. Form 3 filings must be submitted within two business days of the insider assuming their position. This particular filing documents te Boekhorst’s option holdings as President and CEO. It creates the foundation for monitoring subsequent stock purchases or sales.
CEO Compensation and Executive Incentives at ICCC
Executive compensation packages typically include base salary, bonuses, and equity grants. Stock options align leadership interests with shareholder value creation. Paul te Boekhorst’s option grant reflects ImmuCell’s approach to retaining top talent.
Non-Qualified Stock Options Explained
Non-qualified stock options (NSOs) grant employees the right to purchase company shares at a predetermined price. Unlike incentive stock options, NSOs receive different tax treatment. The holder pays ordinary income tax on the spread between exercise price and fair market value. NSOs offer companies greater flexibility in compensation design. They’re commonly used for executive retention and performance alignment.
Market Context for ICCC Stock
ImmuCell Corporation trades with a market capitalization of $74.6 million. The company operates in the biotech sector, focusing on animal health solutions. The $5.90 exercise price reflects the company’s valuation at the grant date. Meyka AI rates ICCC stock a grade of B, indicating moderate fundamentals. Executive option grants at this price level suggest management confidence in future performance.
What This Insider Transaction Reveals
Insider transactions provide windows into executive sentiment about company prospects. When leaders receive equity compensation, it typically signals confidence in long-term value creation. The ICCC filing offers several analytical insights.
Leadership Confidence Signals
Paul te Boekhorst’s option grant demonstrates the board’s commitment to retaining experienced leadership. The September 2028 vesting date suggests a multi-year performance horizon. This extended timeline indicates management expects sustained business operations. Option grants to sitting CEOs typically reflect board confidence in strategic direction. The grant size and pricing align with market standards for biotech firms of ICCC’s scale.
Insider Activity Patterns
This transaction represents an initial ownership filing rather than a buy or sell activity. The filing establishes te Boekhorst’s baseline holdings for SEC tracking purposes. Future Form 4 filings will disclose any subsequent purchases, sales, or option exercises. Monitoring these patterns helps investors understand executive conviction. Regular insider buying often precedes positive company announcements.
Investor Implications and Monitoring ICCC
Insider transaction filings help investors assess management alignment and confidence levels. Understanding these filings requires knowledge of SEC forms and transaction types. ICCC shareholders should track future insider activity closely.
How to Monitor Future ICCC Insider Trades
Investors can access SEC filings through the EDGAR database or financial platforms. Form 4 filings report actual purchases, sales, and option exercises by insiders. Form 5 filings capture transactions exempt from Form 4 reporting requirements. Setting alerts for ICCC insider activity helps track leadership sentiment. Regular monitoring reveals patterns in executive buying or selling behavior.
Key Metrics for ICCC Analysis
The $149,441 option grant represents meaningful compensation for the CEO role. At current market cap levels, this grant reflects approximately 0.2% of company value. Investors should compare this grant size to industry peers and historical patterns. Tracking option exercise prices versus actual stock prices reveals value creation. These metrics inform investment decisions and risk assessment for ICCC shareholders.
Final Thoughts
Paul Francis Olivier te Boekhorst’s non-qualified stock option grant at ImmuCell Corporation signals management confidence in the company’s future. The 25,329-share grant at $5.90 per share represents standard executive compensation in the biotech sector. This Form 3 filing establishes the baseline for tracking the CEO’s future transactions. Investors should monitor subsequent Form 4 filings to assess whether te Boekhorst exercises options or makes additional purchases. The filing demonstrates board commitment to retaining experienced leadership at ICCC, a company rated B by Meyka AI. Understanding insider transactions helps investors gauge executive sentiment and alignment with s…
FAQs
A Form 3 is an initial ownership statement filed by insiders within two business days of assuming a position. It establishes baseline security holdings and creates the foundation for tracking future transactions by directors, officers, and major shareholders.
Non-qualified stock options (NSOs) grant employees the right to purchase company shares at a set price with different tax treatment than incentive stock options. They’re commonly used for executive compensation and provide flexibility in structuring employee incentive packages.
Stock option grants align executive interests with shareholder value creation, incentivize long-term performance, and retain key talent. They provide tax-efficient compensation while motivating leaders to improve company performance and stock price.
Investors can monitor ICCC insider activity through the SEC EDGAR database or financial platforms using Form 4 filings, which report purchases, sales, and option exercises. Setting alerts helps track management sentiment about the company.
Paul Francis Olivier te Boekhorst serves as Director, President, and CEO of ImmuCell Corporation, leading strategic direction and operations. His insider filings carry significant weight in assessing management confidence in company prospects.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)